Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

This study has been terminated.
(Funding constraints)
Sponsor:
Information provided by (Responsible Party):
Erimos Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00664586
First received: April 21, 2008
Last updated: February 20, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2009
  Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)